◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Invesco Asia Dragon Trust Ord (IAD) Financial History

Name: Invesco Asia Dragon Trust Ord (IAD) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Investment Trusts · DATA UPDATED 2026-10-06

Invesco Asia Dragon Trust Ord (IAD) operates in the Investment Trusts industry. Its market capitalization is roughly £1 billion. In the fiscal year ended 2026-04-30, IAD reported £289M in revenue and £282M in net income.

Interactive charts & full statements →

IAD Revenue & Earnings History — Annual Income Statement

Income statement	2026-04-30	2025-04-30	2024-04-30	2023-04-30	2022-04-30
Total Revenue	£289M	(£19M)	£8M	£5M	—
Net Income	£282M	(£25M)	£6M	£3M	—

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

IAD Free Cash Flow History

IAD Balance Sheet History

Balance sheet	2026-04-30	2025-04-30	2024-04-30	2023-04-30	2022-04-30
Total Assets	£1.0B	£777M	£253M	£261M	—
Total Liabilities	£42M	£47M	£14M	£16M	—

GBP; £M / £B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive IAD viewer.

Other Companies in Software & IT Services

CGI · Canadian General Investments Ord — C$1 billion
CPAC · Cementos Pacasmayo S.A.A. American Depositary Shares (Each representing five Common Shares) — $1 billion
BBNX · Beta Bionics, Inc. - — $1 billion
AGT · AVI Global Trust Ord — £1 billion
EDIN · Edinburgh Investment Ord — £1 billion
MRCH · Merchants Trust Ord — £968 million
UPBD · Upbound Group, Inc. - — $916 million
CRVS · Corvus Pharmaceuticals, Inc. - — $903 million

← IACO All “I” companies IAEA →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.